| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SIGLEC6 |
| Uniprot No | O43699 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 16-320aa |
| 氨基酸序列 | LLPLLWAGALAQERRFQLEGPESLTVQEGLCVLVPCRLPTTLPASYYGYG YWFLEGADVPVATNDPDEEVQEETRGRFHLLWDPRRKNCSLSIRDARRRD NAAYFFRLKSKWMKYGYTSSKLSVRVMALTHRPNISIPGTLESGHPSNLT CSVPWVCEQGTPPIFSWMSAAPTSLGPRTTQSSVLTITPRPQDHSTNLTC QVTFPGAGVTMERTIQLNVSYAPQKVAISIFQGNSAAFKILQNTSSLPVL EGQALRLLCDADGNPPAHLSWFQGFPALNATPISNTGVLELPQVGSAEEG DFTCR |
| 预测分子量 | 60 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SIGLEC6重组蛋白的3篇参考文献及其摘要概括：
1. **标题**：*"Recombinant SIGLEC6-Fc Fusion Protein Suppresses B-cell Activation via CD22 Interaction"*
**作者**：Smith A, et al.
**摘要**：该研究通过哺乳动物细胞表达系统制备了SIGLEC6-Fc重组蛋白，证实其通过结合CD22抑制B细胞受体信号通路，提示其在自身免疫疾病治疗中的潜力。
2. **标题**：*"Structural and Functional Analysis of Recombinant SIGLEC6 Reveals Its Role in Trophoblast Invasion"*
**作者**：Zhang Y, et al.
**摘要**：作者解析了SIGLEC6重组蛋白的晶体结构，发现其与胎盘滋养层细胞侵袭相关配体结合，可能参与妊娠期免疫耐受调节，为子痫前期机制研究提供新线索。
3. **标题**：*"SIGLEC6 Recombinant Protein Attenuates Mast Cell Degranulation in Allergic Models"*
**作者**：Tanaka K, et al.
**摘要**：研究证明SIGLEC6重组蛋白通过竞争性结合唾液酸化的过敏原，抑制肥大细胞活化，为过敏性疾病治疗提供了实验依据。
*注：以上文献信息为模拟示例，实际引用需核对真实出版物。建议通过PubMed或Web of Science以"SIGLEC6 recombinant protein"为关键词检索最新研究。*
**Background of SIGLEC6 Recombinant Protein**
SIGLEC6 (sialic acid-binding immunoglobulin-type lectin 6) is a transmembrane protein belonging to the SIGLEC family, which comprises immune-regulatory receptors primarily involved in recognizing sialylated glycans. Encoded by the *SIGLEC6* gene, it is predominantly expressed in placental trophoblasts and B cells, suggesting roles in immune modulation and cellular signaling. Structurally, SIGLEC6 contains an N-terminal V-set immunoglobulin domain that mediates sialic acid binding, followed by C2-set Ig domains, a transmembrane region, and a cytoplasmic tail harboring immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These motifs enable recruitment of phosphatases like SHP-1/SHP-2. facilitating inhibitory signaling pathways.
SIGLEC6’s interaction with sialylated ligands, such as glycoprotein hormones or tumor-associated antigens, regulates immune cell activity. In placental tissue, it may contribute to maternal-fetal tolerance by suppressing immune responses at the maternal-fetal interface. In B cells, it potentially modulates B-cell receptor signaling. Dysregulated SIGLEC6 expression has been linked to pathologies, including preeclampsia and B-cell malignancies, highlighting its therapeutic relevance.
Recombinant SIGLEC6 protein is engineered for research and therapeutic development. Produced via mammalian expression systems (e.g., CHO or HEK293 cells), it retains post-translational modifications critical for ligand-binding activity. Purified recombinant protein enables functional studies, including ligand interaction assays, receptor signaling analysis, and antibody development. Its applications extend to exploring immune evasion mechanisms in cancers, designing targeted therapies, and studying pregnancy-related disorders. As a tool, recombinant SIGLEC6 aids in deciphering its dual roles in immune homeostasis and disease, offering potential for diagnostic and therapeutic advancements.
×
